header

A pharmaceutical study on certain poorly soluble antihypertensive drug / (Record no. 63146)

MARC details
000 -LEADER
fixed length control field 02160cam a2200313 a 4500
003 - CONTROL NUMBER IDENTIFIER
control field EG-GiCUC
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 171028s2017 ua d f m 000 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency EG-GiCUC
Language of cataloging eng
Transcribing agency EG-GiCUC
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
049 ## - LOCAL HOLDINGS (OCLC)
Holding library Deposite
097 ## - Thesis Degree
Thesis Level Ph.D
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
Classification number Cai01.08.08.Ph.D.2017.As.P
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Asmaa Abdelaziz Mohamed Bayoumi
245 12 - TITLE STATEMENT
Title A pharmaceutical study on certain poorly soluble antihypertensive drug /
Statement of responsibility, etc. Asmaa Abdelaziz Mohamed Bayoumi ; Supervised Mohamed Aly Kassem , Magdi Ibrahim Mohamed
246 15 - VARYING FORM OF TITLE
Title proper/short title دراسة صيدلية على شحيح الذوبان معين خافض لضغط الدم
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Cairo :
Name of publisher, distributor, etc. Asmaa Abdelaziz Mohamed Bayoumi ,
Date of publication, distribution, etc. 2017
300 ## - PHYSICAL DESCRIPTION
Extent 265 P. :
Other physical details charts ;
Dimensions 25cm
502 ## - DISSERTATION NOTE
Dissertation note Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
520 ## - SUMMARY, ETC.
Summary, etc. Azilsartan kamedoxomil is a selective angiotensin II receptor antagonist, type1 (AT1) competi-tive antagonist. The US Food and Drug Administration (FDA) has approved Edarbi tablet (Azilsartan Medoxomil Potassium) on February 25, 2011, to treat hypertension in adults. It is available in 80 mg and 40 mg dosages. Many patients may prefer the oral route of administration to the more invasive other treatment options that includes injections especially if the oral formula could achieve a rapid onset of action. Azilsartan kamedoxomil is a poorly water soluble belongs to Biopharmaceutical Classification System (BCS class IV). One of the major problems of this drug is low solubility in biological flu-ids, which results in poor bioavailability after oral administration. Hence, its solubility should be enhanced to increase its bioavailability. In this work, azilsartan kamedoxomil was formulated in the form of rapidly dissolving stable tablets using different technique.
530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE
Additional physical form available note Issued also as CD
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term Antihypertensive drug
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term Azilsartan kamedoxomil
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term Certain poorly soluble
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Magdi Ibrahim Mohamed ,
Relator term
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Mohamed Aly Kassem ,
Relator term
905 ## - LOCAL DATA ELEMENT E, LDE (RLIN)
Cataloger Nazla
Reviser Revisor
905 ## - LOCAL DATA ELEMENT E, LDE (RLIN)
Cataloger Shimaa
Reviser Cataloger
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Thesis
Holdings
Source of classification or shelving scheme Not for loan Home library Current library Date acquired Full call number Barcode Date last seen Koha item type Copy number
Dewey Decimal Classification   المكتبة المركزبة الجديدة - جامعة القاهرة قاعة الرسائل الجامعية - الدور الاول 11.02.2024 Cai01.08.08.Ph.D.2017.As.P 01010110073021000 22.09.2023 Thesis  
Dewey Decimal Classification   المكتبة المركزبة الجديدة - جامعة القاهرة مخـــزن الرســائل الجـــامعية - البدروم 11.02.2024 Cai01.08.08.Ph.D.2017.As.P 01020110073021000 22.09.2023 CD - Rom 73021.CD